HPV Vaccination in India: Critical Appraisal
Aruna Nigama b✉, Pikee Saxenac, Anita Shankar Acharyad, Archana Mishrac, Swaraj Batraa
- aDepartment of Obstetrics and Gynaecology, Hamdard Institute of Medical Sciences and Research, New Delhi 110062, India
- bReader’s Flat No. 4, Lady Hardinge Medical College Campus, New Delhi 110001, India
- cDepartment of Obstetrics and Gynaecology, Lady Hardinge Medical College, New Delhi 110001, India
- dDepartment of Preventive and Social Medicine, Lady Hardinge Medical College, New Delhi 110001, India
- ✉Corresponding author
Papers open inside SciRah from the original publisher or repository; SciRah never hosts them.
Abstract
Cervical cancer is the third most common cancer in women worldwide. The role of human papilloma virus (HPV) in the genesis of cervical carcinoma is well documented. The HPV 16 and 18 are found to be most commonly associated with invasive cervical carcinoma. The advent of cervical carcinoma vaccine has advanced the hopes that eradication of cervical carcinoma might be possible in future. The scenario of prevention of cervical carcinoma is completely different in developed and developing countries. The implementation of the vaccination as a routine in India is still controversial. Here we have tried to critically analyse these issues in Indian context. However it is clear that cervical cancer vaccine is not an immediate panacea and cannot replace the cervical cancer screening which is mandatory in Indian context.
TL;DRIt is clear that cervical cancer vaccine is not an immediate panacea and cannot replace the cervical cancer screening which is mandatory in Indian context. (Semantic Scholar)